Our aim was to determine whether genetic polymorphisms in the CALB2 gene and in the genes coding for miRNA and transcription factors regulating calretinin expression are associated with MM susceptibility or serum calretinin levels in patients with asbestos-related diseases. This evidence concerns the gene CALB2 and Miyoshi myopathy.